These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9645913)

  • 21. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
    D'Angelo SV; Gilardoni F; D'Angelo A
    Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway.
    Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Pabinger-Fasching I; Mannhalter C; Jilma B; Speiser W
    Thromb Res; 1997 Sep; 87(6):501-10. PubMed ID: 9330432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA.
    Tripodi A; Chantarangkul V; Clerici M; Mannucci PM
    Thromb Haemost; 2002 Oct; 88(4):583-6. PubMed ID: 12362227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.
    Petäjä J; Fernández JA; Gruber A; Griffin JH
    J Clin Invest; 1997 Jun; 99(11):2655-63. PubMed ID: 9169495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulant response to activated protein C: method validation and assay comparison.
    Calkins T; Greengard J; Griffin JH; Bylund D
    J Clin Lab Anal; 1995; 9(6):418-23. PubMed ID: 8587012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid removal of platelets from plasma utilizing the Hepcheck heparin removal filter.
    McGlasson DL; Ledford M; Barna L; Best HA; Hickman JR
    Blood Coagul Fibrinolysis; 1997 Jan; 8(1):16-20. PubMed ID: 9105633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to activated protein C: evaluation of three functional assays.
    Vasse M; Leduc O; Borg JY; Chrétien MH; Monconduit M
    Thromb Res; 1994 Oct; 76(1):47-59. PubMed ID: 7817360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma.
    Tripodi A; Chantarangkul V; Negri B; Mannucci PM
    Thromb Haemost; 1998 Mar; 79(3):564-6. PubMed ID: 9531041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
    Svensson PJ; Zöller B; Dahlbäck B
    Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technical and biological conditions influencing the functional APC resistance test.
    Freyburger G; Bilhou-Nabera C; Dief S; Javorschi S; Labrouche S; Lerebeller MJ; Boisseau MR
    Thromb Haemost; 1996 Mar; 75(3):460-5. PubMed ID: 8701408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An improved test to identify aPC-resistant factor V-Leiden.
    Preda L; Erba N; Figini S; Carniti GC; Rossi E
    Thromb Res; 1997 Jun; 86(6):461-8. PubMed ID: 9219326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants.
    Denis-Magdelaine A; Flahault A; Verdy E
    Haemostasis; 1995; 25(3):98-105. PubMed ID: 7607585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit.
    De Stefano V; Paciaroni K; Mastrangelo S; Rutella S; Bizzi B; Leone G
    Thromb Haemost; 1996 May; 75(5):752-6. PubMed ID: 8725718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants.
    Alving BM; Baldwin PE; Richards RL; Jackson BJ
    Thromb Haemost; 1985 Oct; 54(3):709-12. PubMed ID: 3937268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
    Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
    Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.